


# VISCHER IN THE THE SALE OF MESTEX AG TO GRÜNENTHAL

*Posted on 21 April 2021*



**Category:** [Deal & transactions](#)

**Tags:** [Christian Wyss](#), [Mestex](#), [Nadia Tarolli](#), [News](#)



Vischer advised the sellers of Mestex AG on all legal issues related to the sale of their shares and stock options to the pharmaceutical company Grünenthal, a global operator in pain management and related diseases.

With the acquisition, Grünenthal aims to grow in the global market for osteoarthritis drugs and further strengthen its pain treatment-focused pipeline.

**Vischer acted with a team led by Christian Wyss (Partner, Corporate/M&A) and Nadia Tarolli (Partner, Tax) with Luzius Zumstein (Associate, Corporate/M&A), Moritz Jäggy (Associate, Corporate/M&A), Pauline Pfirter (Associate, Corporate/M&A), and Adrian Briner (Associate, Tax).**

In all matters of German law, Vischer was supported by Orrick Herrington & Sutcliffe led by **Jörg Ritter** and **Christine Kaniak**.

Mestex is a the Swiss biotech company developing, among other things, the novel compound MTX-071 (resiniferatoxin) for the intra-articular treatment of pain associated with osteoarthritis of the knee. The promising drug candidate MTX-071 is about to enter phase III clinical trials and could provide an innovative treatment option for millions of patients suffering from pain associated with knee osteoarthritis.